|
Health Canada Warns Consumers
Not To Use Neophase Formula For Men Due To Potential
Health Risks
August
4, 2006
Health Canada is warning consumers
not to use Neophase Formula for Men, which has
been found to contain an undeclared ingredient
similar to the active pharmaceutical ingredient
found in Viagra. The use of this product could
pose serious health risks, especially for patients
with existing medical conditions such as heart
problems, those taking heart medications, or those
who may be at risk for strokes.
Neophase Formula for Men is advertised
as a natural sex enhancer for men. The product
was analyzed by the U.S. Food and Drug Administration
and found to contain homosildenafil, a modified
form of sildenafil, which should only be used
under medical supervision. The use of products
containing sildenafil has also been associated
with serious side-effects including sudden vision
loss, penile tissue damage and urinary tract infection.
This product has been found on the
Canadian market but is not authorized for sale
in Canada. The Canadian distributor has been contacted
and is recalling the product. Consumers who may
have purchased Neophase Formula for Men are warned
not to use it, and should consult with a health
care professional if they have used it and have
concerns about their health.
Neophase Formula for Men is manufactured
in the U.S. by Vigor Nutriceutical Healthcare
Inc. in Wisconsin.
Health Canada also advises Canadians
to contact the Health Products and Food Branch
Inspectorate at 1-800-267-9675 if they find Neophase
Formula for Men in Canada. Health Canada has notified
the Canada Border Services Agency to detain any
shipment of Neophase Formula for Men at the border.
Consumers requiring more information
about this advisory can contact Health Canada’s
public enquiries line at (613) 957-2991, or toll
free at 1-866-225-0709.
To date, no adverse reactions suspected
to be associated with the use of this product
have been reported in Canada. To report a suspected
adverse reaction with this or any other health
product, please contact the Canadian Adverse Drug
Reaction Monitoring Program (CADRMP) of Health
Canada by one of the following methods:
Telephone: 1-866-234-2345
Facsimile: 1-866-678-6789
CADRMP
Marketed Health Products Directorate
Health Protection Building, Tunney’s Pasture,
AL 0701C
Ottawa, Ontario K1A 0K9
Email: cadrmp@hc-sc.gc.ca
|
